Study Title
Evaluate Durvalumab and Tremelimumab +/?- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3)
Purpose
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma.
For more information please visit
https://clinicaltrials.gov/study/NCT05301842
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at 318-212-8671.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
** WK New Format
IRB Number:
Trial Type:
Device
Sponsor:
** WK New Format
Contact Information: